Nygren, JM, Jovinge, S, Breitbach, M, Säwén, P, Röll, W, Hescheler, J et al.. Bone marrow-derived hematopoietic cells generate cardiomyocytes at a low frequency through cell fusion, but not transdifferentiation. Nat Med 10: 494-501

Hematopoietic Stem Cell Laboratory, Lund Strategic Research Center for Stem Cell Biology and Cell Therapy, Lund University, BMC B10, Klinikgatan 26, 221 84 Lund, Sweden.
Nature Medicine (Impact Factor: 27.36). 06/2004; 10(5):494-501. DOI: 10.1038/nm1040
Source: PubMed


Recent studies have suggested that bone marrow cells might possess a much broader differentiation potential than previously appreciated. In most cases, the reported efficiency of such plasticity has been rather low and, at least in some instances, is a consequence of cell fusion. After myocardial infarction, however, bone marrow cells have been suggested to extensively regenerate cardiomyocytes through transdifferentiation. Although bone marrow-derived cells are already being used in clinical trials, the exact identity, longevity and fate of these cells in infarcted myocardium have yet to be investigated in detail. Here we use various approaches to induce acute myocardial injury and deliver transgenically marked bone marrow cells to the injured myocardium. We show that unfractionated bone marrow cells and a purified population of hematopoietic stem and progenitor cells efficiently engraft within the infarcted myocardium. Engraftment was transient, however, and hematopoietic in nature. In contrast, bone marrow-derived cardiomyocytes were observed outside the infarcted myocardium at a low frequency and were derived exclusively through cell fusion.

Download full-text


Available from: Jalal Taneera, May 20, 2014
  • Source
    • "When they injected HSC into mice that underwent myocardial infarction, they did not observe any differentiation into cardiac myocytes. Injected cells simply differentiated into U n c o r r e c t e d P a p e r i n P r e s s the blood cells (Balsam et al., 2004), or fused with the cardiac cells (Nygren et al., 2004). Any beneficial effect could not be thus ascribed to the differentiation potential of bone marrow cells. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Stem cells are self-renewing cells that can differentiate into specialized cell type(s). Pluripotent stem cells, i.e. embryonic stem cells (ESC) or induced pluripotent stem cells (iPSC) differentiate into cells of all three embryonic lineages. Multipotent stem cells, like hematopoietic stem cells (HSC), can develop into multiple specialized cells in a specific tissue. Unipotent cells differentiate only into one cell type, like e.g. satellite cells of skeletal muscle. There are many examples of successful clinical applications of stem cells. Over million patients worldwide have benefited from bone marrow transplantations performed for treatment of leukemias, anemias or immunodeficiencies. Skin stem cells are used to heal severe burns, while limbal stem cells can regenerate the damaged cornea. Pluripotent stem cells, especially the patient-specific iPSC, have a tremendous therapeutic potential, but their clinical application will require overcoming numerous drawbacks. Therefore, the use of adult stem cells, which are multipotent or unipotent, can be at present a more achievable strategy. Noteworthy, some studies ascribed particular adult stem cells as pluripotent. However, despite efforts, the postulated pluripotency of such events like "spore-like cells", "very small embryonic-like stem cells" or "multipotent adult progenitor cells" have not been confirmed in stringent independent studies. Also plasticity of the bone marrow-derived cells which were suggested to differentiate e.g. into cardiomyocytes, has not been positively verified, and their therapeutic effect, if observed, results rather from the paracrine activity. Here we discuss the examples of recent studies on adult stem cells in the light of current understanding of stem cell biology.
    Acta biochimica Polonica 07/2015; 62(3). DOI:10.18388/abp.2015_1023 · 1.15 Impact Factor
  • Source
    • "In this paper, they demonstrated cardiac differentiation of transplanted HSCs; but this result was not confirmed by other groups [23] [24]. Instead, it emerged that HSCs generate cardiomyocytes with low frequency by fusion with resident cells [25] [26] but not by active cardiac differentiation. Emerging roles in cardiac disease therapies have been demonstrated for hematopoietic cytokines like GCSF, granulocyte macrophage colony-stimulating factor (GM-CSF), SCF, Flt-3 ligand, and erythropoietin (EPO). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Bone marrow-derived mesenchymal stem cells (BM-MSCs) are valuable platforms for new therapies based on regenerative medicine. BM-MSCs era is coming of age since the potential of these cells is increasingly demonstrated. In fact, these cells give origin to osteoblasts, chondroblasts, and adipocyte precursors in vitro, and they can also differentiate versus other mesodermal cell types like skeletal muscle precursors and cardiomyocytes. In our short review, we focus on the more recent manipulations of BM-MSCs toward skeletal and heart muscle differentiation, a growing field of obvious relevance considering the toll of muscle disease (i.e., muscular dystrophies), the heavier toll of heart disease in developed countries, and the still not completely understood mechanisms of muscle differentiation and repair.
    BioMed Research International 06/2014; 2014:762695. DOI:10.1155/2014/762695 · 2.71 Impact Factor
  • Source
    • "Evidence suggests that the microenvironment of injury could affect the migration, adherence and differentiation of transplanted stem cells [31-33]. Transplanted stem cells might transdifferentiate to tissue-specific cells, or fuse with the existing native cells, to improve the organ function by contributing their own genetic and cellular materials [33,34]. The development of ovarian follicles requires complex cell-cell interactions, as well as communication between somatic and germ cells. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Ovarian dysfunction frequently occurs in female cancer patients after chemotherapy, but human amniotic epithelial cells (hAECs) that can differentiate into cell types that arise from all three germ layers may offer promise for restoration of such dysfunction. Previous studies confirmed that hAECs could differentiate into cells that express germ cell-specific markers, but at this time hAECs have not been shown to restore ovarian function. To model premature ovarian failure, hAECs infected with lenti-virus carrying green fluorescent protein were injected into the tail vein of mice sterilized with cyclophosphamide and busulphan. hAECs migrated to the mouse ovaries and overall ovarian function was measured using immunohistochemical techniques. Seven days to two months after hAECs transplantation, ovarian cells were morphologically restored in sterilized mice. Hemotoxylin and eosin staining revealed that restored ovarian cells developed follicles at all stages. No follicles were observed in control mice at the same time period. Immunostaining with anti-human antigen antibodies and pre-transplantation labeling with green fluorescent protein (GFP) revealed that the grafted hAECs survived and migrated to mouse ovary, differentiating into granulosa cells. Furthermore, the ovarian function marker, anti-Müllerian hormone, was evident in treated mouse ovaries after hAEC transplantation. Intravenously injected hAECs reached the ovaries of chemotherapy-treated mice and restored folliculogenesis, data which suggest promise for hAECs for promoting reproductive health and improving the quality of life for female cancer survivors.
    Stem Cell Research & Therapy 10/2013; 4(5):124. DOI:10.1186/scrt335 · 3.37 Impact Factor
Show more